JP2021529753A5 - - Google Patents

Info

Publication number
JP2021529753A5
JP2021529753A5 JP2020572903A JP2020572903A JP2021529753A5 JP 2021529753 A5 JP2021529753 A5 JP 2021529753A5 JP 2020572903 A JP2020572903 A JP 2020572903A JP 2020572903 A JP2020572903 A JP 2020572903A JP 2021529753 A5 JP2021529753 A5 JP 2021529753A5
Authority
JP
Japan
Prior art keywords
macrophages
monocytes
activity
target
copy number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020572903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529753A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039773 external-priority patent/WO2020006385A2/en
Publication of JP2021529753A publication Critical patent/JP2021529753A/ja
Publication of JP2021529753A5 publication Critical patent/JP2021529753A5/ja
Pending legal-status Critical Current

Links

JP2020572903A 2018-06-29 2019-06-28 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法 Pending JP2021529753A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862692463P 2018-06-29 2018-06-29
US62/692,463 2018-06-29
US201962810683P 2019-02-26 2019-02-26
US62/810,683 2019-02-26
US201962857199P 2019-06-04 2019-06-04
US62/857,199 2019-06-04
US201962867532P 2019-06-27 2019-06-27
US62/867,532 2019-06-27
PCT/US2019/039773 WO2020006385A2 (en) 2018-06-29 2019-06-28 Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof

Publications (2)

Publication Number Publication Date
JP2021529753A JP2021529753A (ja) 2021-11-04
JP2021529753A5 true JP2021529753A5 (OSRAM) 2022-07-05

Family

ID=68985243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572903A Pending JP2021529753A (ja) 2018-06-29 2019-06-28 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法

Country Status (10)

Country Link
US (1) US20210189342A1 (OSRAM)
EP (1) EP3813881A4 (OSRAM)
JP (1) JP2021529753A (OSRAM)
KR (1) KR20210040948A (OSRAM)
CN (1) CN113164589A (OSRAM)
AU (2) AU2019293600A1 (OSRAM)
BR (1) BR112020026386A2 (OSRAM)
CA (1) CA3103154A1 (OSRAM)
TW (1) TW202023629A (OSRAM)
WO (1) WO2020006385A2 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020079484A1 (en) * 2018-10-19 2020-04-23 Regenics As Use of egg cellular extract for wound healing
WO2020172631A2 (en) 2019-02-21 2020-08-27 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
JP7716992B2 (ja) 2019-06-04 2025-08-01 ヴェルソー セラピューティクス， インコーポレイテッド 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
AU2020306772A1 (en) * 2019-06-27 2022-02-17 Verseau Therapeutics, Inc. Anti-LRRC25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
JP2022540768A (ja) * 2019-06-27 2022-09-20 ヴェルソー セラピューティクス， インコーポレイテッド 骨髄細胞炎症性表現型を調節するための抗ｃｄ５３組成物及び方法、ならびにその使用
JP7678802B2 (ja) 2019-11-04 2025-05-16 アレクトル エルエルシー Ｓｉｇｌｅｃ－９ＥＣＤ融合分子及びその使用方法
EP4084807A4 (en) * 2019-12-30 2024-04-10 University of Pittsburgh - of the Commonwealth System of Higher Education Intrapancreatic m2 polarization of macrophages to treat type 1 diabetes
CA3167921A1 (en) * 2020-01-28 2021-08-05 Nanotomer, Inc. Clathrin-chimeric antibody receptor constructs for immune cell activation therapy in vivo
US11642629B2 (en) * 2020-03-20 2023-05-09 Saudi Arabian Oil Company Multi-layer composite gas separation membranes, methods for preparation, and use
US20230104315A1 (en) * 2020-03-27 2023-04-06 Boundless Bio, Inc. Method of identifying extrachromosomal dna signatures
MX2022013093A (es) 2020-04-20 2022-11-14 Duogenic Stemcells Corp Macrofagos modificados, composiciones y usos de los mismos.
WO2021263115A1 (en) * 2020-06-26 2021-12-30 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cancer, overcoming pd-1/pd-l1 blockade resistance, and determining resistance to checkpoint inhibitor treatment
CN112837306B (zh) * 2021-02-20 2022-11-22 薛竟宜 基于深度学习和中智理论的冠状动脉病变功能学定量方法
CN113884682B (zh) * 2021-04-30 2023-07-21 中国医学科学院血液病医院(中国医学科学院血液学研究所) 检测巨核细胞或血小板表面标志分子的产品在制备检测感染的产品中的用途
US20240335500A1 (en) * 2021-07-23 2024-10-10 University Of Florida Research Foundation, Incorporated Controlling pro-inflammatory macrophage phenotype through biofunctional hydrogel design
CN113897397B (zh) * 2021-09-30 2024-04-02 中南大学 一种基于DNAzyme调控基因编辑的方法
CN114010666B (zh) * 2021-10-22 2024-05-07 上海交通大学 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用
CN113913507A (zh) * 2021-10-29 2022-01-11 温州医科大学附属第一医院 Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用
CN114214237B (zh) * 2021-12-23 2023-06-16 南京大学 一种洗脱细胞表面吸附纳米颗粒的方法
CN115029473B (zh) * 2022-06-21 2024-06-18 湖北省药品监督检验研究院 一种基于mlpa技术对中药材桃仁与苦杏仁进行鉴别的方法
CN115739182B (zh) * 2022-11-17 2024-01-16 合肥机数量子科技有限公司 含单分散铁原子的过氧化物模拟酶及其制备方法和用途
WO2024189098A1 (en) 2023-03-13 2024-09-19 Iomx Therapeutics Ag Platform technology for the identification of modulators of immune effector cell function
CN116403649A (zh) * 2023-03-17 2023-07-07 中山大学附属第六医院 一种igsf6基因在免疫治疗治疗系统中的应用
EP4684016A2 (en) * 2023-03-20 2026-01-28 The Regents of the University of California Methods and materials for treating cancer
CN117159495A (zh) * 2023-08-16 2023-12-05 北京大学 脂质纳米颗粒及其应用
TWI873056B (zh) * 2024-07-01 2025-02-11 國立成功大學 採用影像分割技術的胃內視鏡影像分析方法與電腦系統

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1742650A1 (en) * 2004-03-30 2007-01-17 Den Kgl.Veterin R-Og Landboh Jskole Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
AU2009246166B2 (en) * 2008-05-15 2014-09-18 Tetherex Pharmaceuticals Corporation Anti-PSGL-1 antibodies and methods of identification and use
WO2011143411A1 (en) * 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
AU2012324847B2 (en) * 2011-10-21 2017-01-12 Transgene Sa Modulation of macrophage activation
WO2015077401A1 (en) * 2013-11-20 2015-05-28 Drexel University Compositions and methods for macrophage conversion
WO2016033527A1 (en) * 2014-08-29 2016-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis
US20160200815A1 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
GB201611535D0 (en) * 2016-07-01 2016-08-17 King S College London Methods and compositions for treating cancer with siglec-9 activity modulators
KR102630011B1 (ko) * 2017-01-11 2024-01-26 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도

Similar Documents

Publication Publication Date Title
Reiss et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Narayan et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
Cohen et al. B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Sato-Kaneko et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer
Luo et al. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept
JP7428397B2 (ja) 免疫調節性ｍ２単球を選択的に低減することによってがんを治療し、治療的免疫を増強するための方法および組成物
Fang et al. Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications
Won et al. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs
Denkert et al. Biomarker data from the phase III KATHERINE study of adjuvant T-DM1 versus trastuzumab for residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer
Lin et al. Cancer therapy resistance mediated by cancer-associated fibroblast-derived extracellular vesicles: biological mechanisms to clinical significance and implications
Orr et al. Phase I trial combining chemokine-targeting with loco-regional chemoimmunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity
Wan et al. MiR-25-3p promotes malignant phenotypes of retinoblastoma by regulating PTEN/Akt pathway
Chen et al. SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production
Grotz et al. Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma
JP2023527410A5 (OSRAM)
Han et al. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti–PD-L1 and lenalidomide in cutaneous T cell lymphoma
Wang et al. Regulation gene expression of miR200c and ZEB1 positively enhances effect of tumor vaccine B16F10/GPI-IL-21 on inhibition of melanoma growth and metastasis
Ma et al. Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies
Wu et al. Effects of exosomes on tumor bioregulation and diagnosis
Patel et al. Progress in personalized immunotherapy for patients with brain metastasis
Ying et al. Exosomal miR-184 facilitates bladder cancer progression by targeting AKR1C3 and inducing immune escape via IRF2-CXCL10 axis
Ramezani et al. Current Understanding of the Exosomes and Their Associated Biomolecules in the Glioblastoma Biology, Clinical Treatment, and Diagnosis
JP2022539038A5 (OSRAM)
de Oliveira Silva et al. New avenues for the treatment of immunotherapy-resistant pancreatic cancer
JP2025003730A (ja) 癌患者への免疫チェックポイント阻害薬の投与の有効性を予測するためのデータを収集する方法